NCT05334654View on ClinicalTrials.gov

Bivalirudin Versus Enoxaparin in Critically Ill COVID-19 Patients

NACompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

April 20, 2022

Primary Completion Date

June 30, 2022

Study Completion Date

July 30, 2022

Conditions
Acute Respiratory FailureSARS CoV 2 InfectionAnticoagulants
Interventions
DRUG

Enoxaparin Sodium

Enoxaparin will be subcutaneously administered at a dosage from 4000 to 8000 twice daily according

DRUG

Bivalirudin

Bivalirudin will be intravenously administered to obtain an activated prothrombin time (aPTT) of 1.5 fold of the normal values.

Trial Locations (1)

Unknown

AOU Mater Domini, Catanzaro

All Listed Sponsors
lead

University Magna Graecia

OTHER